Probiodrug

  • Probiodrug completed a sub-10% private placement by issuing new shares priced at market levels
  • Proceeds will be used for the preparations of further clinical development of its lead product PQ912
  • Kempen & Co’s efforts resulted in a well-covered book made up of long-term specialist investors